E-viri
PDF
Recenzirano
Odprti dostop
-
Shitara, Kohei; Bang, Yung-Jue; Iwasa, Satoru; Sugimoto, Naotoshi; Ryu, Min-Hee; Sakai, Daisuke; Chung, Hyun-Cheol; Kawakami, Hisato; Yabusaki, Hiroshi; Lee, Jeeyun; Saito, Kaku; Kawaguchi, Yoshinori; Kamio, Takahiro; Kojima, Akihito; Sugihara, Masahiro; Yamaguchi, Kensei
The New England journal of medicine, 06/2020, Letnik: 382, Številka: 25Journal Article
Approximately 15 to 20% of gastric adenocarcinomas express HER2. Trastuzumab deruxtecan is an antibody-drug conjugate composed of trastuzumab and the topoisomerase I inhibitor deruxtecan. In a randomized trial, the antibody-drug conjugate led to higher response and longer overall survival than physician’s choice of therapy among patients with relapsed disease.
